Phase 1 Study for Safety and Tolerability of IL-1-Ra Topically Administered to Eyes of Healthy Adult Subjects

NCT03383276 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

34

Enrollment

OTHER

Sponsor class

Conditions

Blepharokeratoconjunctivitis

Interventions

DRUG: IL-1Ra

Sponsor

Beijing Tongren Hospital

Collaborators

[object Object]